NO20072173L - Fremgangsmate for fremstilling av 4-{4-[({[4-klor-3-(trifluormetyl)fenyl]amino}karbonyl)amino] fenoksy}-N-metylpyridin-2-karboksamid - Google Patents

Fremgangsmate for fremstilling av 4-{4-[({[4-klor-3-(trifluormetyl)fenyl]amino}karbonyl)amino] fenoksy}-N-metylpyridin-2-karboksamid

Info

Publication number
NO20072173L
NO20072173L NO20072173A NO20072173A NO20072173L NO 20072173 L NO20072173 L NO 20072173L NO 20072173 A NO20072173 A NO 20072173A NO 20072173 A NO20072173 A NO 20072173A NO 20072173 L NO20072173 L NO 20072173L
Authority
NO
Norway
Prior art keywords
amino
chloro
formula
compound
methylpyridine
Prior art date
Application number
NO20072173A
Other languages
English (en)
Other versions
NO339647B1 (no
Inventor
Matthias Mueller-Gliemann
Reinhold Gehring
Werner Heilmann
Mathias Berwe
Michael Loegers
Oliver Kuhn
Mike Matthaeus
Klaus Mohrs
Juergen Stiehl
Hana Lenz
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072173(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20072173L publication Critical patent/NO20072173L/no
Publication of NO339647B1 publication Critical patent/NO339647B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av 4-{4-[({ [4-kloro-3-(trifluorometyl)fenyl]arrrino}karbonyl)arnino]fenoksy}-Af-metylpyridin-2-karboksamid og dets tosylatsalt. Formel (I), som innbefatter, i et første trinn, omsetting av forbindelsen med formel (V) med 4-kloro-3-trifluorometylfenyl-isocyanat i et ikke-klorert organisk løsemiddel, inert overfor isocyanater, ved initielt å tilsette forbindelsen med formel (V) ved en temperatur på fra 20°C til 60°C og blande sammen med 4-kloro-3-trifluorometylfenyl-isocyanat på en slik måte at reaksjonstemperaturen ikke overskrider 70°C for å gi forbindelsen med formel (II) og, i et andre trinn, blande forbindelsen med formel (II) sammen med p-toluensulfonsyre i et polart løsemiddel ved en reaksjonstemperatur på fra 40°C og opp til reflukstemperaturen til anvendt løsemiddel.
NO20072173A 2004-09-29 2007-04-26 Fremgangsmåte for fremstilling av 4-{4-[({[4-kloro-3-(trifluorometyl)-fenyl]amino}karbonyl)amino]fenoksy}-N-metylpyridin-2-karboksamid og dets tosylatsalt NO339647B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29
PCT/EP2005/010118 WO2006034796A1 (en) 2004-09-29 2005-09-20 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Publications (2)

Publication Number Publication Date
NO20072173L true NO20072173L (no) 2007-06-14
NO339647B1 NO339647B1 (no) 2017-01-16

Family

ID=35457568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072173A NO339647B1 (no) 2004-09-29 2007-04-26 Fremgangsmåte for fremstilling av 4-{4-[({[4-kloro-3-(trifluorometyl)-fenyl]amino}karbonyl)amino]fenoksy}-N-metylpyridin-2-karboksamid og dets tosylatsalt

Country Status (35)

Country Link
US (1) US8124782B2 (no)
EP (1) EP1797037B1 (no)
JP (2) JP2008514657A (no)
KR (1) KR101263032B1 (no)
CN (1) CN101052619B (no)
AR (1) AR053973A1 (no)
AU (1) AU2005289099B2 (no)
BR (1) BRPI0515944B1 (no)
CA (1) CA2581835C (no)
CU (1) CU23754B7 (no)
CY (1) CY1116126T1 (no)
DK (1) DK1797037T3 (no)
DO (1) DOP2005000183A (no)
EC (1) ECSP077357A (no)
ES (1) ES2532377T3 (no)
GT (1) GT200500269A (no)
HK (1) HK1113484A1 (no)
HN (1) HN2005000768A (no)
HR (1) HRP20150295T1 (no)
IL (1) IL182046A0 (no)
MA (1) MA28883B1 (no)
MY (1) MY149873A (no)
NO (1) NO339647B1 (no)
NZ (1) NZ554119A (no)
PE (5) PE20091586A1 (no)
PL (1) PL1797037T3 (no)
PT (1) PT1797037E (no)
SG (1) SG155997A1 (no)
SI (1) SI1797037T1 (no)
SV (1) SV2006002243A (no)
TW (1) TWI382973B (no)
UA (1) UA90691C2 (no)
UY (1) UY29143A1 (no)
WO (1) WO2006034796A1 (no)
ZA (1) ZA200702511B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
WO2006034796A1 (en) 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
JP5304241B2 (ja) 2005-03-07 2013-10-02 バイエル・ヘルスケア・エルエルシー 癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
EP2195286A2 (en) 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
WO2009054004A2 (en) * 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
US8217061B2 (en) 2008-01-17 2012-07-10 Sicor Inc. Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US20090253913A1 (en) * 2008-03-06 2009-10-08 Pierluigi Rossetto Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CA2775296A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2011058522A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
CA2788146C (en) 2010-01-29 2014-11-25 Ranbaxy Laboratories Limited Sorafenib dimethtyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
GT200000002AA (es) * 1999-01-13 2007-06-15 Ureas difenilicias x-carboxiaril sustituidas como inhibidores de raf quinasa
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
ES2275931T5 (es) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1842852A1 (en) * 2002-08-13 2007-10-10 Sandoz AG A cefdinir intermediate
PT1559715E (pt) * 2002-10-21 2007-10-24 Kirin Pharma Kk Formas cristalinas de sais de n-[2-cloro-4-[6, 7-dimetoxi-4-quinolil)oxi]finil]-n'-(5-metil-3-isoxazolil) ureia
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
WO2006034796A1 (en) 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Also Published As

Publication number Publication date
EP1797037B1 (en) 2014-12-17
UA90691C2 (en) 2010-05-25
CU23754B7 (es) 2012-01-31
ECSP077357A (es) 2007-04-26
PL1797037T3 (pl) 2015-07-31
SI1797037T1 (sl) 2015-06-30
PE20060825A1 (es) 2006-10-20
CN101052619B (zh) 2012-02-22
CU20070069A7 (es) 2010-11-27
EP1797037A1 (en) 2007-06-20
DOP2005000183A (es) 2006-03-31
JP5583190B2 (ja) 2014-09-03
ES2532377T3 (es) 2015-03-26
TW200626551A (en) 2006-08-01
PT1797037E (pt) 2015-03-17
JP2008514657A (ja) 2008-05-08
PE20091584A1 (es) 2009-10-28
NO339647B1 (no) 2017-01-16
UY29143A1 (es) 2006-04-28
HK1113484A1 (en) 2008-10-03
BRPI0515944B1 (pt) 2021-11-09
NZ554119A (en) 2010-07-30
CN101052619A (zh) 2007-10-10
WO2006034796A1 (en) 2006-04-06
PE20091587A1 (es) 2009-11-05
SG155997A1 (en) 2009-10-29
MA28883B1 (fr) 2007-09-03
PE20091586A1 (es) 2009-10-31
AR053973A1 (es) 2007-05-30
SV2006002243A (es) 2006-10-13
KR20070058676A (ko) 2007-06-08
BRPI0515944A (pt) 2008-08-12
MY149873A (en) 2013-10-31
CY1116126T1 (el) 2017-02-08
HRP20150295T1 (hr) 2015-05-22
ZA200702511B (en) 2008-07-30
US8124782B2 (en) 2012-02-28
PE20091585A1 (es) 2009-10-31
KR101263032B1 (ko) 2013-05-09
DK1797037T3 (en) 2015-03-30
IL182046A0 (en) 2007-07-24
US20080262236A1 (en) 2008-10-23
AU2005289099A1 (en) 2006-04-06
GT200500269A (es) 2006-05-11
CA2581835A1 (en) 2006-04-06
TWI382973B (zh) 2013-01-21
AU2005289099B2 (en) 2012-07-19
JP2013067625A (ja) 2013-04-18
HN2005000768A (es) 2010-09-17
CA2581835C (en) 2012-12-18

Similar Documents

Publication Publication Date Title
NO20072173L (no) Fremgangsmate for fremstilling av 4-{4-[({[4-klor-3-(trifluormetyl)fenyl]amino}karbonyl)amino] fenoksy}-N-metylpyridin-2-karboksamid
Bremerich et al. Additions to N‐Sulfinylamines as an Approach for the Metal‐free Synthesis of Sulfonimidamides: O‐Benzotriazolyl Sulfonimidates as Activated Intermediates
Wei et al. A Broad‐Spectrum Catalytic Amidation of Sulfonyl Fluorides and Fluorosulfates
Kong et al. Direct catalytic decarboxylative amination of aryl acetic acids
PE20040516A1 (es) Derivados de 1,2-azol
NO20065441L (no) Fremgangsmate for fremstilling av atazanavir-bisulfat og nye varianter
PE20060699A1 (es) Forma termodinamicamente estable de una sal tosilato
ATE401073T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
Rouzi et al. Synthesis of N-sulfonylformamidines by tert-butyl hydroperoxide–promoted, metal-free, direct oxidative dehydrogenation of aliphatic amines
Xie et al. Synthesis of α, α-difluoro-β-amino carbonyl-containing sulfonamides and related compounds
WO2007003603A3 (de) Fungizide mischungen auf der basis von 3-monosubstituierten pyrazolcarbonsäurebiphenylamiden
EP1897875A1 (en) Process for producing 1-pyridin-4-YL-indoles
EA201170809A1 (ru) Способ получения производных пиперазина
Sumii et al. Synthesis of Aryl Triflones through the Trifluoromethanesulfonylation of Benzynes
ES2722854A1 (es) Procedimiento para preparar n-((1r,2s,5s)-2-((2-((5-cloropiridin-2-il)amino)-2-oxoacetil)amino)-5-(dimetilcarbamoil) ciclohexil)carbamato de terc-butilo
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
DK2219999T3 (da) Krystalliseret IZM-3-fast stof og fremgangsmåde til fremstilling deraf
Lam et al. Copper-catalyzed synthesis of functionalized aryl sulfonamides from sodium sulfinates in green solvents
PE20030978A1 (es) Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico
JP6762124B2 (ja) トリフルオロメチルチオ化剤、トリフルオロメチルチオ化方法、ならびにｎ−（置換スルホニル）−ｎ−［（トリフルオロメチル）チオ］置換スルホンアミド化合物
JP2007530478A5 (no)
CN106699646A (zh) 啶虫脒合成方法
Brosse et al. N-tert-Butoxycarbonylaminophthalimide, a versatile reagent for the conversion of alcohols into alkylated tert-butylcarbazates or hydrazines via the Mitsunobu protocol
WO2011004242A3 (en) An improved process for the preparation of dutasteride
DK1558560T3 (da) Fremgangsmåde til fremstilling af 2,6-dihalogen-para-trifluormenthylanilin

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER HEALTHCARE LLC, US